2025-06-11-Jefferies-联合健康集团（UNH）_亨斯利任务艰巨_但股票仍有上行空间_18页_742kb

UnitedHealth Group (UNH) Equity Research Summary

Investment Recommendation

• Rating: Buy
• Price Target: $399, projecting a +31% upside from the current price of $303.79. Valuation supports this via Sum of the Parts (SOTP) analysis, yielding fair value at $390.

Investment Thesis

• UNH's Managed Care (MA) business benefits from market share growth and profitable expansion, underpinned by digitization and AI-driven cost efficiencies.
• MA member growth is expected to resume in 2027, with improved rates supporting margin recovery.
• The company leverages digitization to defend margins despite low premium yields, presenting a strong long-term thesis.

Key Challenges and Risks

• MLR Pressures: UNH faces higher Medical Loss Ratio (MLR) due to V28 coding headwinds, estimated at 125bps annually, significantly above peer averages. This stems from elevated risk-adjusted premiums (RAF) and business mix, resulting in MLR pressures 250bps higher than Humana (HUM).
• Marginal Erosion: Full-risk margins in OptumHealth (OHealth) are currently negative (LSD-MSD% range), with V28 contributing to a net annual h'wind of 5.0%, partially offset by rate increases and maturation.
• Supplementary Dynamics: "Super-switchers" attracted low-margin dual-eligible members through rich supplemental benefits, exacerbating top-line pressure, though this is not financially material for the whole business.

Financial Recovery and Projections

• EPS Recovery: Expected ~$6 of EPS power between 2026 and 2027, driven by a generous 2026 rate increase and reduced V28 impact.
• Marginal Improvement: OHealth is projected to return to >7% margins by 2027, following stabilization from V28 headwinds.
• Timing of Rate Deficiency and Cohort Maturation May Differ from Street Estimates.

Valuation

• Methodology: SOTP analysis breaks down segments (e.g., MA, Commercial, Optum) with applied multiples, yielding $390 fair value. Target multiple is ~13x 2027E EPS, inline with historical averages.
• Sensitivity: Downside scenarios consider persistent V28 pressure and regulatory overhaul, supported by base case, upside (+89% to $573), and downside (-33% to $204) PTs.

Risks

• Utilization & Acuity: Medical cost and utilization trends could negate margin gains, especially with ongoing coding reforms.
• Regulatory and Market Factors: Competitive consolidation risks, potential recession dampening commercial enrollment, and regulatory actions could pressure MLR and growth.
• Structural Concerns: Unanswered questions on the UHC-OHealth integration, with G&A efficiencies potentially fading after 2025.

End of Summary.